Navigation Links
Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
Date:3/23/2010

DALLAS March 23, 2010 Human pancreatic cancer cells dramatically regress when treated with chemotherapy in combination with a synthetic compound that mimics the action of a naturally occurring "death-promoting" protein found in cells, researchers at UT Southwestern Medical Center have found.

The research, conducted in mice, appears in today's issue of Cancer Research and could lead to more effective therapies for pancreatic and possibly other cancers, the researchers said.

"This compound enhanced the efficacy of chemotherapy and improved survival in multiple animal models of pancreatic cancer," said Dr. Rolf Brekken, associate professor of surgery and pharmacology and the study's senior author. "We now have multiple lines of evidence in animals showing that this combination is having a potent effect on pancreatic cancer, which is a devastating disease."

In this study, Dr. Brekken and his team transplanted human pancreatic tumors into mice, then allowed the tumors to grow to a significant size. They then administered a synthetic compound called JP1201 in combination with gemcitabine, a chemotherapeutic drug that is considered the standard of care for patients with pancreatic cancer. They found that the drug combination caused regression of the tumors.

"There was a 50 percent regression in tumor size during a two-week treatment of the mice," Dr. Brekken said. "We also looked at survival groups of the animals, which is often depressing in human therapeutic studies for pancreatic cancer because virtually nothing works. We found not only significant decrease in tumor size, but meaningful prolongation of life with the drug combination."

The drug combination was also effective in an aggressive model of spontaneous pancreatic cancer in mice.

The compound JP1201 was created in 2004 by UT Southwestern researchers to mimic the action of a protein called Smac. The researchers discovered Smac in 2000 and found that this protein plays a key role in the normal self-destruction process present in every cell.

Cell death, or apoptosis, is activated when a cell needs to be terminated, such as when a cell is defective or is no longer needed for normal growth and development. In cancer cells, this self-destruct mechanism is faulty and lead to breaks in the cell-death cascade of events. The synthetic Smac, or Smac mimetic, developed at UT Southwestern inhibits these breaks, allowing the cell to die.

"In essence, we're inhibiting an inhibitor," Dr. Brekken said. "And we're allowing the apoptotic cascade to kick off, resulting in the death of cancer cells."

UT Southwestern researchers are using Smac mimetics in breast and lung cancer research, as well. Dr. Brekken said the next step is to develop a compound based on JP1201 that can be tested in humans in clinical trials.


'/>"/>

Contact: Connie Piloto
connie.piloto@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers find new chemotherapy combination shows promise in endometrial cancer
2. Study evaluates costs and benefits of new chemotherapy drugs
3. Scientists identify microRNA as possible cause of chemotherapy resistance
4. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
5. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
6. Breast cancer multigene test helping patients avoid chemotherapy
7. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
8. Criteria based on CT imaging after chemotherapy may help predict survival
9. Synthetic, dissolving plates ease repairs of nasal septum defects
10. Synthetic Platelets Put the Brakes on Blood Loss
11. Synthetic Red Blood Cells Developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... for customers and employees that are both engaging and easy to use. Coming ... Technology, the software company revealed today its plans to roll out new AI-powered ...
(Date:12/8/2016)... ... , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services from ... Messina. , Among the recognitions, the American College of Surgeons' (ACS) named the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... soon after surgery as possible. With this in mind, SIGVARIS has created a ... or blood clot) during bed rest and provide the benefits of graduated compression ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... -- Mitsubishi Tanabe Pharma Corporation (Head Office: ... Masayuki Mitsuka ) has presented data that show ... in 10-14 day cycles for 48 weeks experienced significantly ... Rating Scale-Revised (ALSFRS-R). The data were presented at the ... Dublin, Ireland . In the ...
(Date:12/9/2016)... HARRISBURG, Pa. , Dec. 9, 2016 ... today announced temporary regulations for medical marijuana dispensaries under ... The Pennsylvania Bulletin , and are now available ... what is needed in the plan for operation; process ... the dispensary; as well as where the dispensary facilities ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
Breaking Medicine Technology: